Piper Jaffray raises price target on AVI BioPharma, says buy on weakness

theflyonthewall.com

Piper Jaffray said top-line results from AVI BioPharma's Phase II trial of Etepliersen in boys with Duchenne's muscular dystrophy were encouraging and recommended buying the shares on weakness. Piper maintains its Overweight rating on the stock and increased its price target on shares to $2.50 from $2.00.

Rates

View Comments (0)